(Q28287394)

1

0 references

L Duplomb

2

0 references

C Ruiz Velasco

3

0 references

Y Fortun

4

0 references

M Padrines

Expert Review of Anticancer Therapy

6

0 references

language of work or name

English

0 references

publication date

February 2007

0 references

published in

0 references

volume

7

0 references

issue

2

0 references

page(s)

221-32

0 references

cites work

Osteoclast and its roles in calcium metabolism and bone development and remodeling

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoclastic acidification pathways during bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

RANKL-RANK signaling in osteoclastogenesis and bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Jun Dimerization Protein 2 (JDP2), a Member of the AP-1 Family of Transcription Factor, Mediates Osteoclast Differentiation Induced by RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Regulatory roles and molecular signaling of TNF family members in osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The signaling adaptors and pathways activated by TNF superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Distinct molecular mechanism for initiating TRAF6 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Self-assembled RANK induces osteoclastogenesis ligand-independently.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

TRAF6 Is a Critical Factor for Dendritic Cell Maturation and Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

21 January 2018

Osteolysis and cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

RANK ligand is a prerequisite for cancer-associated osteolytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Malignant melanoma and bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The pharmacology of bisphosphonates and new insights into their mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Bisphosphonates: new therapeutic agents for the treatment of bone tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Severe hypocalcaemia after being given intravenous bisphosphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Role of osteoprotegerin (OPG) in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Osteoprotegerin in prostate cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221

Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.221